Upregulating CD59: A new strategy for protection of neurons from complement-mediated degeneration

Pharmacogenomics Journal

Volumn 10, Issue 1, 2010, Pages 12-19

  Kolev, M V ^a   Tediose, T ^a   Sivasankar, B ^a   Harris, C L ^a   Thome, J ^b   Morgan, B P ^a   Donev, R M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

CD59; Complement lysis; Complement regulators; Neural restrictive silencer factor (NRSF; Neurodegeneration; Neuroprotection; REST)

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; NEURAL RESTRICTIVE SILENCER FACTOR DERIVED PEPTIDE; PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL PROTECTION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOLYSIS; DRUG DESIGN; DRUG MECHANISM; DRUG RESEARCH; HUMAN; HUMAN CELL; IMMUNOMODULATION; NERVE CELL DEGENERATION; NERVE CELL DIFFERENTIATION; NERVE CELL LESION; NEUROBLASTOMA CELL; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; WILD TYPE;

AMINO ACID SEQUENCE; ANTIGENS, CD59; CELL DEATH; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; NEURONS; PEPTIDES; REPRESSOR PROTEINS; UP-REGULATION; ZINC FINGERS;

EID: 75549083769     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.52     Document Type: Article

References (33)

1. Walport MJ. Advances in immunology: complement (first of two parts). N Engl J Med 2001; 344: 1058-1066.
2. Gasque P, Neal J, Singhrao S, McGreal E, Dean Y, Van B et al. Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities. Mol Neurobiol 2002; 25: 1-17.
3. Barnum S. Complement biosynthesis in the central nervous system. Crit Rev Oral Biol Med 1995; 6: 132-146.
4. Silva C, Rio M, Cruz C. Local immunoglobulin synthesis and blood-brain barrier assessment in subacute sclerosing panencephalitis. Eur Neurol 1985; 24: 128-133.
5. Gasque P, Fontaine M, Morgan B. Complement expression in human brain-biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol 1995; 154: 4726-4733.
6. Gasque P, Julen N, Ischenko A, Picot C, Mauger C, Chauzy C et al. Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 1992; 149: 1381-1387.
7. Morgan B, Gasque P. Extrahepatic complement biosynthesis: where, when and why? Clin Exp Immunol 1997; 107: 1-7.
8. Hosokawa M, Klegeris A, Maguire J, McGeer P. Expression of complement messenger RNAs and proteins by human oligodendroglial cells. Glia 2003; 42: 417-423.
9. Martino G, Adorini L, Rieckmann P, Hillert J, Kallmann B, Comi G et al. Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol 2002; 1: 499-509.
10. Kolev M, Ruseva M, Harris C, Morgan B, Donev R. Implication of complement system and its regulators in Alzheimer's disease. Curr Neuropharmacol 2009; 7: 1-8.
11. Osaka H, Mukherjee P, Aisen P, Pasinetti G. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem 1999; 73: 303-311.
12. Pasinetti G. Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Neurobiol Aging 1996; 17: 707-716.
13. Mead R, Singhrao S, Neal J, Lassmann H, Morgan B. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol 2002; 168: 458-465.
14. Mead R, Neal J, Griffiths M, Linington C, Botto M, Lassmann H et al. Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Lab Invest 2004; 84: 21-28.
15. Vedeler C, Ulvestad E, Bjørge L, Conti G, Williams K, Mørk S et al. The expression of CD59 in normal human nervous tissue. Immunology 1994; 82: 542-547.
16. Pasinetti G, Johnson S, Oda T, Rozovsky I, Finch C. Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J Comp Neurol 1994; 339: 387-400.
17. Singhrao S, Neal J, Rushmere N, Morgan B, Gasque P. Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol 2000; 157: 905-918.
18. Gasque P, Morgan B. Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes. Immunology 1996; 89: 338-347.
19. Yang L, Li R, Meri S, Rogers J, Shen Y. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J Neurosci 2000; 20: 7505-7509.
20. Donato R, Miljan E, Hines S, Aouabdi S, Pollock K, Patel S et al. Differential development of neuronal physiological responsiveness in two human neural stem cell lines. BMC Neurosci 2007; 8: 36.
21. Harris C, Williams A, Linton S, Morgan B. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol 2002; 129: 198-207.
22. Donev RM, Cole DS, Sivasankar B, Hughes TR, Morgan BP. p53 regulates cellular resistance to complement lysis through enhanced expression of CD59. Cancer Res 2006; 66: 2451-2458.
23. Donev R, Gray L, Sivasankar B, Hughes T, van den Berg C, Morgan B. Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma. Cancer Res 2008; 68: 5979-5987.
24. Shimojo M, Hersh LB. REST/NRSF-interacting LIM domain protein, a putative nuclear translocation receptor. Mol Cel Biol 2003; 23: 9025-9031.
25. Shimojo M, Lee JH, Hersh LB. Role of zinc finger domains of the transcription factor neuron-restrictive silencer factor/repressor element-1 silencing transcription factor in DNA binding and nuclear localization. J Biol Chem 2001; 276: 13121-13126.
26. Harris C, Hughes C, Williams A, Goodfellow I, Evans D, Caterson B et al. Generation of anti-complement 'prodrugs': cleavable reagents for specific delivery of complement regulators to disease sites. J Biol Chem 2003; 278: 36068-36076.
27. Lee K, Luu N, Kaneski C, Schiffmann R, Brady R, Murray G. Improved intracellular delivery of glucocerebrosidase mediated by the HIV-1 TAT protein transduction domain. Biochem Biophys Res Commun 2005; 337: 701-707.
28. Westbrook T, Hu G, Ang X, Mulligan P, Pavlova N, Liang A et al. SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 2008; 452: 370-374.
29. Johnson D, Mortazavi A, Myers R, Wold B. Genome-wide mapping of in vivo protein-DNA interactions. Science 2007; 316: 1497-1502.
30. Weissman A. How much REST is enough? Cancer Cell 2008; 13: 381-383.
31. Singhrao S, Neal J, Rushmere N, Morgan B, Gasque P. Differential expression of individual complement regulators in the brain and choroid plexus. Lab Invest 1999; 79: 1247-1259.
32. Lucas S, Rothwell N, Gibson R. The role of inflammation in CNS injury and disease. Br J Pharmacol 2006; 147(Suppl 1): S232-S240.
33. Maier M, Peng Y, Jiang L, Seabrook T, Carroll M, Lemere C. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/ macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 2008; 28: 6333-6341.